Peripheral Metabolic Effects of Somatostatin

Not Applicable

Completed

• Conditions: Acromegaly; Growth Hormone Deficiency; Diabetes
• Interventions: Drug: Somatostatin

• Registration Number: NCT01062529
• Lead Sponsor: University of Aarhus

Brief Summary

The aim of this study is to investigate peripheral effects of Somatostatin on glucose metabolism and growth hormone (GH) signalling in healthy men. Eight subjects will be enrolled. The hypothesis is that Somatostatin infusion reverses insulin resistance caused by GH.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-10
• Study First Submitted: 2010-01-28
• Primary Completion: 2010-02
• Study Completion: 2010-02
• Study First Submitted QC: 2010-02-03
• Study First Posted: 2010-02-04
• Status Verified: 2013-01
• Last Update Submitted: 2013-01-18
• Last Update Posted: 2013-01-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 8

Inclusion Criteria

• BMI < 27 kg/m2
• Written informed consent
• Healthy

Exclusion Criteria

• Any disease
• Any use of medications
• Present or previous malignancy
• Alcohol dependency
• Allergy to trial medication

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
somatostatin	Somatostatin	-

Primary Outcome Measures

Name	Time	Method
Plasma levels of glucose	3 months

Secondary Outcome Measures

Name	Time	Method
GH signalling	one year
Serum levels of free fatty acids (FFA)	one year

Trial Locations

Locations (1)

Medical department M; 🇩🇰 Aarhus, Denmark